TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05083169
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be administered SC injection.
Study: NCT05083169
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide will be administered orally.
Study: NCT05083169
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered orally or intravenously.
Study: NCT05083169
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered SC injection.
Study: NCT05083169
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab will be administered SC injection.
Study: NCT05000853
Drug: Iron Carboxymaltose
Normalized name: Iron carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Iron supplementation when is needed according to usual care
Study: NCT05628857
Drug: RC108
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
Study: NCT04841811
Drug: Almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy
Study: NCT04908475
Drug: Risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection
Study: NCT04908475
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Tablets
Study: NCT05249621
Drug: MZE001
Normalized name: MZE001
DrugBank: MZE001 (DB17701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule inhibitor of muscle glycogen synthase
Study: NCT04408508
Drug: Amoxicillin 250 MG
Normalized name: amoxicillin 250 MG
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose oral amoxicillin will be administered to patients enrolled in the study meeting the inclusion and exclusion criteria.
Study: NCT06010368
Drug: Tranexamic acid injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In TXA group (n=75): 1 g from tranexamic acid (kapron®, Amoun, Egypt) shall also be watered down in 10 cc of Saline, and 5 cc shall be injected in each uterine corn before the placenta is separated.
Study: NCT06010368
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the oxytocin group (n = 75): 5 I.U of oxytocin (syntocinone 5 I.U/1ML NONARTIS-EGYPT) shall be watered down in 10 cc of saline, and 5 cc shall be injected into each uterine corn before the placental separation
Study: NCT05928689
Drug: Propranolol Hydrochloride tablet
Normalized name: Propranolol Hydrochloride Tablets
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 40 mg propranolol tablet
Study: NCT06415383
Drug: Vitamin B6 100 MG
Normalized name: vitamin B6 100 MG
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 in for the form of pyridoxal phosphate (PLP)
Study: NCT00002437
Drug: Cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002437
Drug: Probenecid
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02556970
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1g intraoperatively
Study: NCT00000215
Drug: Pergolide
Normalized name: Pergolide
DrugBank: Pergolide (DB01186)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05415644
Drug: hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High-specification group: subject preparation: HRX0701 (50 mg/1000 mg) 1 tablet (to be taken after a meal); Reference preparation: 1 tablet of retagliptin phosphate (50 mg), 2 tablets of metformin hydrochloride (Glucophage®) (500 mg), taken twice after meals.~Low Specification Group:~Preparation: HRX0701 (50 mg/850 mg) 1 tablet (taken after a meal); Reference: 1 tablet of retagliptin phosphate (50 mg), 1 tablet of metformin hydrochloride (Glucophage®) (850 mg), taken twice after meals.
Study: NCT05806164
Drug: Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The beta-agonist oral medication will be prescribed and dose adjusted per usual care.
Study: NCT06003426
Drug: BMS-986278
Normalized name: BMS-986278
DrugBank: BMS-986278 (DB18011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06003426
Drug: BMS-986278 Placebo
Normalized name: BMS-986278
DrugBank: BMS-986278 (DB18011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05298423
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m\^2 administered as an IV infusion in combination with pemetrexed on Day 1 of Cycles 1-3 for non-squamous histology only; In combination with etoposide, cisplatin 50 mg/m\^2 is administered on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3
Study: NCT05298423
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m\^2 administered as an IV infusion on Day 1 of Cycles 1-3 for non-squamous histology only
Study: NCT05298423
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 50 mg/m\^2 is administered as an IV infusion on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3;
Study: NCT05298423
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
Study: NCT05298423
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m\^2 on Day 1 of Cycle 1 and 45 mg/m\^2 on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
Study: NCT05045404
Drug: Poziotinib Hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Poziotinib (DB12114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE~Given PO
Study: NCT04641702
Drug: Atropine challenge
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine challenge. After baseline FLIP, subjects will be administered 15 mcg/kg of intravenous atropine. Two minutes after administration, FLIP will be repeated.
Study: NCT05816759
Drug: CKD-383
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT06328725
Drug: EN001
Normalized name: ReN001
DrugBank: ReN001 (DB05236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1~* Cohort 1: EN001 5.0x10\^5 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~* Cohort 2: EN001 2.5x10\^6 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~Phase 2~* Experimental Group: The recommended phase 2 dose (RP2D) of EN001 is administered intravenously (IV) three times at six-week intervals.~* Control Group: EN001 placebo is administered intravenously (IV) three times at six-week intervals.
Study: NCT04624672
Drug: Semaglutide (1 Mg Dose)
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly injection of study drug for 4-6 months prior to Roux-en-Y gastric bypass surgery
Study: NCT05071664
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab will be administered as a SC injection.
Study: NCT05071664
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab will be administered as a SC injection.
Study: NCT05279118
Drug: ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH is the current standard therapy for children with west syndrome. Those who have been randomised to this arm will be started on high dose ACTH for 2 weeks followed by gradual tapering over remaining 4 weeks and primary response documented at 6 weeks of therapy. The high dose ACTh is 150U/m2 or 6U/kg dose administered IM daily for two weeks. After this the doses will be tapered gradually and ACTH will be stopped by 4 weeks for a total treatment duration of strictly 6 weeks.
Study: NCT05644353
Drug: Mirikizumab
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05728619
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration.
Study: NCT05599230
Drug: Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will daily perform home spirometry and complete a respiratory symptoms score before (3 days) and during (first 14 days) ETI treatment.
Study: NCT05468697
Drug: Belzutifan
Normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg tablet administered orally at a dose of 120 mg.
Study: NCT05468697
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75, 100, or 125 mg tablet administered orally according to randomized dose for 21 days consecutive days followed by 7 days off.
Study: NCT05116891
Drug: CAN04 (nadunolimab)
Normalized name: Nadunolimab
DrugBank: Nadunolimab (DB18249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP
Study: NCT05116891
Drug: DTX
Normalized name: DTX301
DrugBank: Avalotcagene ontaparvovec (DB16796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTX/CAN04
Study: NCT04694300
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg by mouth every 6 hours as needed for pain
Study: NCT06213324
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine dissolved in 100 mL saline, delivered intravenously
Study: NCT04937907
Drug: Hydroxychloroquine Sulfate 100 milligram (mg) Tab
Normalized name: hydroxychloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day at least 6 months.
Study: NCT04937907
Drug: Benazepril hydrochloride 10 milligram (mg) Tab
Normalized name: benazepril
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.
Study: NCT06504524
Drug: Elranatamab
Normalized name: ELRANATAMAB
DrugBank: Elranatamab (DB15395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMA-CD3 bispecific antibody
Study: NCT04891809
Drug: Isatuximab-Irfc 20 MG/ML [Sarclisa]
Normalized name: isatuximab-irfc 20 MG/ML [Sarclisa]
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction: 10mg/kg on day 1,8,15,22 in cycle 1, subsequently on day 1, 15; every 28 days (q28 days) Maintenance: 10mg/kg, day1, q28 days until progression or intolerance but for a maximum of 24 cycles from start of maintenance
Study: NCT04891809
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction: 25mg\*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance~\*) for patients with moderate renal impairment (30≤ GFR (MDRD formula) \< 50 mL/min) starting dose is 10 mg
Study: NCT04891809
Drug: Dexamethasone Oral
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction:~Patients aged \<75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly
Study: NCT05657444
Drug: Tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intra-arterial tenecteplase during endovascular treatment
Study: NCT06114511
Drug: BL-M07D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT05279417
Drug: ATI-450 50 mg oral tablet BID
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, small molecule MK2 inhibitor
Study: NCT05279417
Drug: ATI-450 20 mg oral tablet BID
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, small molecule MK2 inhibitor
Study: NCT05959109
Drug: Peresolimab
Normalized name: Peresolimab
DrugBank: Peresolimab (DB18874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05469022
Drug: Neoadjuvant lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib 240mg p.o once daily.
Study: NCT03435939
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/day for 7 days followed by 100 mg/day for 12 weeks
Study: NCT05929248
Drug: Telitacicept
Normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160mg once a week for 48 weeks
Study: NCT06070350
Drug: Tranexamic Acid (TXA)
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TXA is a synthetic lysine analog that competitively inhibit activation of plasminogen, thereby decreasing the conversion of plasminogen to plasmin, preventing degradation of fibrin's matrix structure. Dose is 25mg/kg IV or IO (maximum 2 grams).
Study: NCT05011097
Drug: Y150
Normalized name: Yohimbine
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive an intravenous infusion of Y150 in a dose escalation once a week for a 28-day treatment cycle until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Study: NCT05165303
Drug: lidocaine with propofol
Normalized name: Propofol
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: different concentrations of lidocaine added to propofol varying from
Study: NCT06366698
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take 1 tablet every other day with lemon/orange juice
Study: NCT05138133
Drug: Anifrolumab
Normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab intravenous infusion (IV)
Study: NCT04986982
Drug: Opicapone 50 mg
Normalized name: opicapone 50 MG
DrugBank: Opicapone (DB11632)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
Study: NCT05134948
Drug: BMS-986213
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT06226896
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10mg daily plus RAS inhibitor
Study: NCT05807542
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
Study: NCT05807542
Drug: Paclitaxel-albumin
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-albumin will be administered on day 1 of each cycle at 260mg/m2 once every 21 days.
Study: NCT05807542
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin will be administered on day 1 of each cycle at AUC=5 once every 21 days.
Study: NCT06149533
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Edoxaban, an oral selective factor Xa inhibitor, had been approved by the National Medical Products Administration in 2018. It is used for the treatment and recurrence prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adults.
Study: NCT05852171
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib administered orally
Study: NCT06154174
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral amoxicillin tablets twice per day for 7 days dosed based on weight
Study: NCT06577493
Drug: Phenazopyridine Hydrochloride 99.5 MG
Normalized name: phenazopyridine hydrochloride 99.5 MG
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arm to take two 99.5 mg phenazopyridine hydrochloride by mouth for a total of 199mg immediately prior to start of urodynamic testing
Study: NCT04582864
Drug: Flotetuzumab
Normalized name: Flotetuzumab
DrugBank: Flotetuzumab (DB15223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be provided by MacroGenics Inc.
Study: NCT06524960
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab is a sterile, preservative-free, clear, colorless to pale yellow solution. Each 1 mL single-dose prefilled syringe of denosumab contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2.
Study: NCT04876313
Drug: Nivolumab + Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4x3 weekly cycles of 360 mg nivolumab + 125 mg/m\^2 nab-paclitaxel IV on days 1 and 8
Study: NCT04876313
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 360 mg IV Q3W x 13 cycles
Study: NCT04854083
Drug: Semaglutide, 1.34 mg/mL
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to semaglutide 1.34mg/ml (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
Study: NCT06525974
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40mg of Febuxostat once daily
Study: NCT06525974
Drug: Mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 g mesalamine three times daily for 3 months.
Study: NCT05434533
Drug: Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV 1gm
Study: NCT06244745
Drug: Administration of letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture.
Study: NCT00002379
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002379
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00002379
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002379
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002379
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04441073
Drug: Lignocaine
Normalized name: Lignocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: preoperative nebulization of lignocaine
Study: NCT06647524
Drug: THC
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be administered 0.5g of vaporized THC cannabis (12% THC cannabis)
Study: NCT04265053
Drug: Ganirelix Acetate
Normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-Releasing Hormone (GnRH) antagonist ganirelix acetate as a model to isolate estrogen and testosterone effects on the cerebrovascular system. Participants receive daily injections of ganirelix for 12-14 days for Aim 3 studies only. This will be overseen by clinical endocrinologists.~Both males and females receive this treatment in Aim 3.
Study: NCT04265053
Drug: Antacid
Normalized name: Antacid
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will also be given a dose of over-the-counter antacid to combat the gastrointestinal distress expected from Indomethacin. Subjects will also be given a dose of over-the-counter antacid during the placebo visit to mimic the indomethacin study visit. Antacid is IND exempt.